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confinement for crystallization from
undersaturated solutions†
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Crystallization from undersaturated solutions was demonstrated
using functionalized nanoporous silica (Zorbax® chromatographic
media). The silica matrix acts as a source of bound groups within
the nanopores which act to reduce the solubility within the small
pore volume resulting in the formation of nanocrystals within the
pores. Experiments were conducted within sealed capillaries which
were monitored via X-ray powder diffraction. Experiments were
conducted for a number of solutes and concentrations and clearly
demonstrated a critical concentration in the undersaturated region
below which crystals would not form. Concentrations above this
critical concentration would form crystals. Batch experiments con-
firmed that the crystallization yield could be calculated from the
difference between the initial concentration before the addition of
Zorbax® and the critical (effective saturation) concentration.
Crystallization is an important separation and purification
technique, especially in the pharmaceutical industry. The
tight regulations on product quality including crystal form,
particle size distribution, crystal shape, purity, and yield
require fine control of the crystallization process.1 The
crystallization process includes both nucleation and growth,
both of which have implications for the end product of the
process. For nucleation to occur, the solution must be
supersaturated, meaning the concentration of solute is
greater than the equilibrium concentration at that given
temperature and solvent condition.2 Supersaturated
conditions are generated most often by changing the solvent
with the addition of an antisolvent or by cooling the solution.
The addition of heterogeneous surfaces to the crystallization
process also changes the dynamics of nucleation.3
Antisolvent crystallization is particularly common in phar-
maceutical processes when the solute or active pharmaceuti-
cal ingredient (API) may be sensitive to changes in tempera-
ture.2 A solute molecule is dissolved in one solvent, typically
at ambient temperature. The addition of an antisolvent to
the solution generates supersaturation because the solute is
less soluble in this new anti-solvent. The choice of anti-
solvent and composition of the solvent/antisolvent mixture
can have implications on crystal size, shape, form, and
yield.4–6 Heterogeneous surfaces can be used to facilitate the
formation of crystal nuclei from supersaturated solutions.
These surfaces may include vessel walls or stirring mecha-
nisms, or seeds of the desired crystal product.7 The activation
energy of nucleation is lowered in these instances due to the
addition of the surface site, corresponding to a decrease in
the surface area of the nuclei in classical nucleation theory.
Templates whose surface chemistries or geometries (such as
self-assembled monolayers, SAMs) are selected to be favor-
able for certain solute crystallizations have been shown to
promote nucleation and growth.8–11 The selection of a sur-
face chemistry can orient solute molecules in addition to pro-
viding a surface site, and thus lower even further the energy
barrier to nucleation. Nanoparticles functionalized with
groups which can act as antisolvents or co-solvents have been
demonstrated to induce crystallization and dissolution re-
versibly, where the solution can be restored to its original
state with the removal of the functionalized nanoparticles.12
Crystallization in confinement has been demonstrated as a
way to produce stable pharmaceutical nanocrystals of a con-
trolled size.13–15 In this approach, crystallization of the API is
restricted to a micro- or nanoporous environment to form
nanocrystals, with contributions to nucleation both from the
confinement of the crystallization volume and heterogeneous
surfaces of the pore. This study combines the effects of crystal-
lization in confinement as well as the principles of heteroge-
neous nucleation and surface functionalization to produce
nanosized crystals from undersaturated solutions. Crystalliza-
tion in pores has been carried out before, however there the
driving force was always present due to antisolvent addition,
evaporation, or cooling crystallization as opposed to this
unique combined effect of surface functionalization and
confinement.
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Zorbax® chromatographic media with C8-like surface
groups was used, to mimic the functional group interaction
of alkanes, which tend to be poor solvents for the organic
APIs chosen for this study. We postulate that in the confined
volumes of the pores of the matrix, the addition of these sur-
face groups rendered a change in the solubility of API in solu-
tion in these nanoscale volumes, providing the driving force
for nucleation and crystallization. This has been applied to
the crystallization of several small molecule organic com-
pounds. Given that the parent solutions are undersaturated,
when held at a fixed temperature left alone or in the presence
of non-functionalized control silica media which mimics the
surface area of the Zorbax® media, the solutions will not
crystallize because there is no driving force for nucleation.
However, we demonstrate that the addition of the functional-
ized Zorbax® media induces crystallization. The confined
nanoscale volumes of the pores have high surface areas, and
thus the expected contribution of the surface
functionalization interaction with the solvent in this environ-
ment is high. We believe the combined surface
functionalization and confinement effect allows for the
Zorbax® media to act as an antisolvent, reducing the solubil-
ity of the APIs and causing nucleation and crystallization.
Zorbax® functionalized chromatographic media was
obtained from Agilent in bulk packing form. This was porous
silica functionalized with a C8-like group (n-
octyldimethylsilane). The average listed grain size of the
beads was 7 μm and the average pore diameter was 7 nm
with a nominal surface area of 160–180 m2 g−1.
Thermogravimetric analysis (TGA) studies were performed on
the Zorbax® to determine the mass loss from C8 groups on
heating and in turn calculate the density of the functional
groups on the pore surface (see the ESI,† for details). The
functional group coverage is of the order of 5 μmole m−2. As
a control, unfunctionalized controlled pore glass (CPG) was
purchased from Prime Synthesis (Aston, PA, USA). This was a
fumed silica with controlled pore size of approximately 12
nm. The average grain size of this material was 100 μm.
First, capillary X-ray powder diffraction (XRPD) studies
were performed to demonstrate that functionalization on the
porous matrix is necessary for crystallization to occur. Three
systems of active pharmaceutical ingredients (APIs) were
studied- diphenhydramine hydrochloride, aspirin and
nicotinamide- in isopropyl alcohol as solvent. The solubility
of each system at 25 °C was determined and is listed in
Table 1 (see ESI† for a discussion of solubility determination
and the procedure for the capillary experiments). Next, solu-
tions of about 85% of the solubility were prepared (actual
concentrations listed in Table 1) and loaded into glass capil-
lary columns in three sets of experiments- without any ma-
trix, with unfunctionalized CPG, and with the functionalized
Zorbax®. The capillaries were sealed to prevent solvent evapo-
ration in order to eliminate any external influences on con-
centration. After a period of 1 hour to allow for any potential
crystallization to occur, each capillary was mounted in a cap-
illary spinner apparatus of the XRPD instrument and
scanned. For comparison, the three dry commercial APIs
were also scanned using capillary XRPD.
For each of the three systems, no crystallization was ob-
served in the capillaries filled simply with the API solutions
without any matrix. This was expected since the solutions
were undersaturated and there were no potential influences
on saturation. Furthermore, the capillaries with
unfunctionalized CPG displayed just an amorphous back-
ground signal from the silica matrix but no presence of crys-
tals. These results demonstrate that confinement effects from
the pores alone, without any functionalization, cannot induce
crystallization in the undersaturated solutions studied.
However, all three systems displayed the presence of crys-
tals in capillaries containing the functionalized Zorbax®. The
results for the first system, diphenhydramine hydrochloride
are shown in Fig. 1 (for the other two systems, see the ESI†).
This demonstrates that the C8 functionalization on the
Zorbax was successful in bringing about crystallization even
from the undersaturated solutions.
It was hypothesized that there exists an effective solubility
of the API in the presence of the functionalized nanoporous
silica, and this solubility is lower than that of the API in pure
solvent. This is responsible for the antisolvent-like behaviour
of the silica matrix. Provided that there is enough matrix
available for crystallization, crystals would grow within the
pores till the API concentration in the mother liquor equili-
brates at the effective solubility value. Hence, feed solutions
with API concentrations above the effective solubility would
crystallize with the addition of Zorbax®, and those with con-
centrations below this value wouldn't crystallize. In other
words, there exists a critical minimum concentration below
Table 1 Solubility at 25 °C and concentration of the solution loaded into
capillaries for XRPD analysis for each of the three API systems
API
Solubility at 25
°C (mg mL−1)
Concentration tested with
capillary XRPD (mg mL−1)
Diphenhydramine
hydrochloride
38.0 30.0
Aspirin 90.0 75.0
Nicotinamide 46.5 40.0
Fig. 1 Diphenhydramine hydrochloride system: XRPD scans for
capillaries containing Zorbax. From top to bottom, dry commercial API,
30 mg mL−1 solution and 25 mg mL−1 solution. No crystallization is
observed in the lowest scan, validating the hypothesis.
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which no crystallization can occur, even in the presence of
the functionalized Zorbax®.
In order to test this hypothesis, solutions of successively
lower concentrations were loaded into capillaries containing
the functionalized Zorbax® and tested for the presence of
crystals. As hypothesized, for each system, crystallization
failed to occur below a certain critical concentration. Results
for diphenhydramine hydrochloride are shown in Fig. 1 (see
ESI† for more details). This critical value lies between the
lowest concentration studied which displays crystallization
and the highest concentration studied which fails to display
any crystallization.
This hypothesis was validated further by performing
batch experiments and determining the mother liquor con-
centration to verify if it matched the critical value from the
capillary XRPD experiments. For each system, 10 mL satu-
rated solutions with Zorbax® added were stirred for 6 h at
25 °C. The amount of Zorbax® added was 1 g for the di-
phenhydramine hydrochloride and the nicotinamide sys-
tems and 1.5 g for the aspirin system. The higher amount
was chosen for the aspirin system to allow for sufficient ma-
trix in view of the higher mass to be crystallized compared
to the other two systems. At the end of the batch run, the
solids were filtered out and the mother liquor concentration
was determined via HPLC (see ESI† for details). In each sys-
tem, the critical value lied in the range predicted from the
capillary XRPD experiments as shown in Table 2, validating
the hypothesis.
To examine if there is any surface crystallization in addi-
tion to crystals confined within the Zorbax® nanopores, the
differential scanning calorimetry (DSC) scan of the post-
crystallization Zorbax® matrix for the diphenhydramine hy-
drochloride system was compared with the scan of bulk API.
Since the melting point of crystals decreases with size, the
presence of nanocrystals can be established by a peak at a
lower melting point compared to that of the bulk API.14–17
Furthermore, in the case of surface crystals in addition to the
confined nanocrystals, there would be two peaks in the DSC
scan- one at the lower melting point corresponding to the
nanocrystals and the other at the same melting point as the
bulk API corresponding to the surface crystals.1 The presence
of a single peak at a lower melting point for the post-
crystallization Zorbax® sample as shown in Fig. 2 proves that
there is no observable surface crystallization and all crystals
are confined to the nanopores. The significant depression in
melting point indicates the nanoscale dimensions of the con-
fined crystals (see ESI† for details).
For the diphenhydramine hydrochloride system, the single
step batch yield at 25 °C starting with a saturated feed solu-
tion (concentration 38 mg mL−1) and ending with a mother
liquor of concentration 26.4 mg mL−1 is about 30% and cor-
responds to a loading of 116 mg API per g Zorbax®. While
the single step yield may be low, the mother liquor can be
concentrated by evaporation and subjected to re-
crystallization with Zorbax® added. This can improve the
overall yield of the process. After each crystallization step,
pure solvent preferably at a higher temperature can be used
to dissolve the crystals from the Zorbax® matrix followed by
filtration of the matrix and subsequent recovery of the API.
This strategy can be employed in synthesis for intermediates
which require a solvent switch or in the purification of an
API or intermediate where an intermediate is crystallized and
then dissolved in a different solvent. As a practical example,
a preparative chromatography column filled with the func-
tionalized nanoporous silica can be operated in a continuous
mode for the purification process.
We believe this work successfully demonstrates that a
surface-functionalized nanoporous media may be used to
provide surface functionality in the confined nano-volumes
of the pores which results in a reduced solubility within the
confined volume resulting in the formation of nanocrystals
within the pores. We believe the most relevant application of
this principle would be in use as a purification technique,
where an impure API or intermediate solution may be flowed
through a column with chosen antisolvent-like functionality
for the API alone to selectively crystallize API within the pores
of the matrix while enriching the flowthrough in impurity.
An eluent solution could be then flowed over the column to
recapture a purer API solution.
Conflicts of interest
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Table 2 Comparison of mother liquor concentration after batch crystal-
lization with the critical minimum concentration range predicted (via cap-
illary XRPD) for crystallization to occur (conc.: concentration). In each
case, the mother liquor concentration lies within the predicted range pro-
vided sufficient matrix is present
API
Mother liquor
concentration (mg
mL−1)
Concentration range
from XRPD (mg mL−1)
Diphenhydramine
hydrochloride
26.4 25–27
Aspirin 66.8 65–70
Nicotinamide 33.2 30–35
Fig. 2 DSC scans show the presence of nanocrystalline DPH with a
depressed melting point from batch experiments with Zorbax®.
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